PVI
ACAD icon

Pura Vida Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Pura Vida Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,000
Closed -$2.58M – 219
2021
Q1 		$2.58M Buy
+100,000
New +$4.4M 0.07% 148

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pura Vida Investments's ACAD Position: Q1 2022 in Review

Pura Vida Investments sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 50,000 shares — an estimated $1.21M sold.

Pura Vida Investments first reported a position in ACAD in Q3 2016 and held it in 2 quarters. The position peaked at $3.92M in Q3 2016. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • Pura Vida Investments reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 50,000 Acadia Pharmaceuticals shares in Q1 2022, an estimated $1.21M.
  • Pura Vida Investments first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Pura Vida Investments's Acadia Pharmaceuticals position peaked at $3.92M in Q3 2016.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.